Adma Biologics (ADMA) Debt to Equity (2016 - 2025)
Adma Biologics' Debt to Equity history spans 13 years, with the latest figure at $0.15 for Q4 2025.
- For Q4 2025, Debt to Equity fell 27.08% year-over-year to $0.15; the TTM value through Dec 2025 reached $0.15, down 27.08%, while the annual FY2025 figure was $0.15, 27.08% down from the prior year.
- Debt to Equity reached $0.15 in Q4 2025 per ADMA's latest filing, down from $0.17 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.41 in Q3 2022 to a low of $0.15 in Q4 2025.
- Average Debt to Equity over 5 years is $0.73, with a median of $0.85 recorded in 2021.
- Peak YoY movement for Debt to Equity: surged 436.23% in 2021, then tumbled 78.54% in 2024.
- A 5-year view of Debt to Equity shows it stood at $0.67 in 2021, then skyrocketed by 39.86% to $0.94 in 2022, then increased by 2.77% to $0.97 in 2023, then crashed by 78.54% to $0.21 in 2024, then dropped by 27.08% to $0.15 in 2025.
- Per Business Quant, the three most recent readings for ADMA's Debt to Equity are $0.15 (Q4 2025), $0.17 (Q3 2025), and $0.18 (Q2 2025).